CN104040341B - 用于前列腺癌的诊断、预测和治疗的游离psa抗体 - Google Patents

用于前列腺癌的诊断、预测和治疗的游离psa抗体 Download PDF

Info

Publication number
CN104040341B
CN104040341B CN201280063852.4A CN201280063852A CN104040341B CN 104040341 B CN104040341 B CN 104040341B CN 201280063852 A CN201280063852 A CN 201280063852A CN 104040341 B CN104040341 B CN 104040341B
Authority
CN
China
Prior art keywords
fpsa
antibody
tumor
prostate cancer
psa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280063852.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104040341A (zh
Inventor
C·索耶斯
D·乌尔默特
J·刘易斯
M·伊万斯
H·丽扎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Priority to CN201611095752.6A priority Critical patent/CN106872702A/zh
Publication of CN104040341A publication Critical patent/CN104040341A/zh
Application granted granted Critical
Publication of CN104040341B publication Critical patent/CN104040341B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/43—Detecting, measuring or recording for evaluating the reproductive systems
    • A61B5/4375—Detecting, measuring or recording for evaluating the reproductive systems for evaluating the male reproductive system
    • A61B5/4381—Prostate evaluation or disorder diagnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4833—Assessment of subject's compliance to treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201280063852.4A 2011-10-25 2012-10-25 用于前列腺癌的诊断、预测和治疗的游离psa抗体 Active CN104040341B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201611095752.6A CN106872702A (zh) 2011-10-25 2012-10-25 用于前列腺癌的诊断、预测和治疗的游离psa抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161551195P 2011-10-25 2011-10-25
US61/551,195 2011-10-25
PCT/US2012/061982 WO2013063312A1 (en) 2011-10-25 2012-10-25 Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201611095752.6A Division CN106872702A (zh) 2011-10-25 2012-10-25 用于前列腺癌的诊断、预测和治疗的游离psa抗体

Publications (2)

Publication Number Publication Date
CN104040341A CN104040341A (zh) 2014-09-10
CN104040341B true CN104040341B (zh) 2016-12-28

Family

ID=48168512

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280063852.4A Active CN104040341B (zh) 2011-10-25 2012-10-25 用于前列腺癌的诊断、预测和治疗的游离psa抗体
CN201611095752.6A Pending CN106872702A (zh) 2011-10-25 2012-10-25 用于前列腺癌的诊断、预测和治疗的游离psa抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201611095752.6A Pending CN106872702A (zh) 2011-10-25 2012-10-25 用于前列腺癌的诊断、预测和治疗的游离psa抗体

Country Status (7)

Country Link
US (3) US20140308204A1 (enExample)
EP (1) EP2771688B1 (enExample)
JP (2) JP6181059B2 (enExample)
CN (2) CN104040341B (enExample)
AU (1) AU2012328679C1 (enExample)
CA (1) CA2853705C (enExample)
WO (1) WO2013063312A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853705C (en) 2011-10-25 2021-10-12 Memorial Sloan-Kettering Cancer Center Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer
CN106794246B (zh) 2014-08-08 2021-10-15 OncoQuest制药有限公司 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
JP6493779B2 (ja) * 2014-09-19 2019-04-03 国立大学法人 岡山大学 ８９Ｚｒの標識方法
US20180326102A1 (en) * 2015-11-18 2018-11-15 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
RS67792B1 (sr) 2016-12-01 2026-03-31 Regeneron Pharma Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje
TWI822719B (zh) * 2017-12-29 2023-11-21 共信醫藥科技股份有限公司 苯磺醯胺衍生物及調節脂膜筏之方法
JP7433249B2 (ja) * 2018-06-01 2024-02-19 イエール ユニバーシティ ステロイドホルモンに関連する疾患または障害を処置するための組成物および方法
CN108802392A (zh) * 2018-08-29 2018-11-13 上海市东方医院 一种用于诊断前列腺癌的层析试纸条及其制备方法和应用
CN114324526B (zh) * 2021-12-27 2023-06-27 青岛农业大学 一种检测人血清中的前列腺特异性抗原的生物传感器及其制备方法和应用
CN118843909A (zh) * 2024-04-02 2024-10-25 嘉兴允英医学检验有限公司 癌症风险等级预测模型生成和预测的方法和系统

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020001588A1 (en) * 1995-08-04 2002-01-03 Sinha Akhouri A. Targeting of organs by immunoconjugates
US6423503B1 (en) * 1999-04-30 2002-07-23 Hybritech Incorporated Forms of free prostate-specific antigen (PSA) and their association with prostate tissues from prostate peripheral zone and transition zone
US20040101914A1 (en) * 2000-09-27 2004-05-27 Kim Pettersson Novel antibody, immunoassay and method for prostate cancer detection
US20060199230A1 (en) * 2005-03-03 2006-09-07 Hybritech Incorporated Use of prostate specific antigen to predict drug response
US20060211059A1 (en) * 2005-03-18 2006-09-21 Taneja Samir S Methods of improving screening, diagnosis and staging of prostate cancer using serum testosterone
CN101137672A (zh) * 2005-02-17 2008-03-05 D·乌尔默特 前列腺癌的诊断
US20100151501A1 (en) * 1997-04-30 2010-06-17 Mikolajczyk Stephen D Forms of Prostate Specific Antigens and Methods for their Detection

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171749A (en) 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
US5173504A (en) 1989-04-21 1992-12-22 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5171741A (en) 1989-04-21 1992-12-15 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5308608A (en) 1989-06-07 1994-05-03 University Of British Columbia Photosensitizing Diels-Alder porphyrin derivatives
SE9002480D0 (sv) 1990-07-23 1990-07-23 Hans Lilja Assay of free and complexed prostate-specific antigen
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5726304A (en) 1992-10-30 1998-03-10 The University Of British Columbia Porphocyanine and CNC-expanded porphyrins
US5405957A (en) 1992-10-30 1995-04-11 The University Of British Columbia Wavelength-specific photosensitive compounds and expanded porphyrin-like compounds and methods of use
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5648485A (en) 1994-10-26 1997-07-15 University Of British Columbia β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins
US5773292A (en) 1995-06-05 1998-06-30 Cornell University Antibodies binding portions, and probes recognizing an antigen of prostate epithelial cells but not antigens circulating in the blood
CZ294715B6 (cs) 1997-05-07 2005-02-16 Qlt Inc. Ethylenglykol estery monohydrobenzoporfyrinových derivátů jako fotoaktivní činidla
US5880145A (en) 1997-05-07 1999-03-09 The University Of British Columbia Class of benzoporphyrin derivative photoactive compounds
US6482599B1 (en) * 1999-04-30 2002-11-19 Hybritech Incorporated Forms of prostate specific antigen (PSA) specific for benign prostatic hyperplasia (BPH) and methods of using such
CN102308212A (zh) * 2008-12-04 2012-01-04 加利福尼亚大学董事会 用于确定前列腺癌诊断和预后的材料和方法
CA2853705C (en) 2011-10-25 2021-10-12 Memorial Sloan-Kettering Cancer Center Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer
US20180326102A1 (en) 2015-11-18 2018-11-15 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020001588A1 (en) * 1995-08-04 2002-01-03 Sinha Akhouri A. Targeting of organs by immunoconjugates
US20100151501A1 (en) * 1997-04-30 2010-06-17 Mikolajczyk Stephen D Forms of Prostate Specific Antigens and Methods for their Detection
US6423503B1 (en) * 1999-04-30 2002-07-23 Hybritech Incorporated Forms of free prostate-specific antigen (PSA) and their association with prostate tissues from prostate peripheral zone and transition zone
US20040101914A1 (en) * 2000-09-27 2004-05-27 Kim Pettersson Novel antibody, immunoassay and method for prostate cancer detection
CN101137672A (zh) * 2005-02-17 2008-03-05 D·乌尔默特 前列腺癌的诊断
US20060199230A1 (en) * 2005-03-03 2006-09-07 Hybritech Incorporated Use of prostate specific antigen to predict drug response
US20060211059A1 (en) * 2005-03-18 2006-09-21 Taneja Samir S Methods of improving screening, diagnosis and staging of prostate cancer using serum testosterone

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
雄激素受体信号途径与前列腺癌;段永顺;《临床泌尿外科杂志》;20010131;第16卷(第1期);第35-37页 *

Also Published As

Publication number Publication date
US20190381200A1 (en) 2019-12-19
CA2853705A1 (en) 2013-05-02
AU2012328679C1 (en) 2018-10-25
CN104040341A (zh) 2014-09-10
EP2771688B1 (en) 2018-09-26
CA2853705C (en) 2021-10-12
CN106872702A (zh) 2017-06-20
WO2013063312A1 (en) 2013-05-02
JP6181059B2 (ja) 2017-08-16
JP2015502339A (ja) 2015-01-22
US12685791B2 (en) 2026-07-21
US20140308204A1 (en) 2014-10-16
EP2771688A1 (en) 2014-09-03
AU2012328679B2 (en) 2018-06-28
JP2017043634A (ja) 2017-03-02
AU2012328679A1 (en) 2014-06-12
US20230040245A1 (en) 2023-02-09
US11446400B2 (en) 2022-09-20
EP2771688A4 (en) 2016-02-17

Similar Documents

Publication Publication Date Title
US20230040245A1 (en) Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer
US12383637B2 (en) Therapeutic agents and uses thereof
Tu et al. Novel GRPR-targeting peptide for pancreatic cancer molecular imaging in orthotopic and liver metastasis mouse models
Sachindra et al. SPECT/CT imaging, biodistribution and radiation dosimetry of a 177Lu-DOTA-integrin αvβ6 cystine knot peptide in a pancreatic cancer xenograft model
Yang et al. Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging
US20160228589A1 (en) Methods and compositions for imaging disorders using polyspecific agents
Pathuri et al. Evaluation of 99mTc-Probestin SPECT as a novel technique for noninvasive imaging of kidney aminopeptidase N expression
BR122022010169B1 (pt) Agentes terapêuticos para uso no tratamento de câncer de próstata e composição farmacêutica

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant